XNW7201 / Evopoint - LARVOL DELTA

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Evopoint Biosciences Inc. | Active, not recruiting ➔ Completed

Metastases • Trial completion • Oncology • Solid Tumor

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=45; Active, not recruiting; Sponsor: Sinovent Pty Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2021 ➔ Jun 2022

Clinical • Enrollment closed • Trial completion date • Oncology • Solid Tumor

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=45; Recruiting; Sponsor: Sinovent Pty Ltd.; Trial completion date: Aug 2021 ➔ Dec 2021; Trial primary completion date: May 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=45; Recruiting; Sponsor: Sinovent Pty Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open